Skip to content

Study · Randomized controlled trial · n = 51 · 2017

3 results

Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.

Kramer CK, Zinman B, Choi H, Connelly PW, Retnakaran R

Diabetes, obesity & metabolism9 Feb 2017Cited by 14 (Europe PMC)

PMID28181363 (opens in a new tab)DOI10.1111/dom.12858 (opens in a new tab)PepBankPUB-28181363
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes, chronic liraglutide did not change the GIP response to an oral glucose challenge versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change the body's own GIP response to a glucose drink compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGIP response (AUC) during OGTT
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no differences in AUCGIP between the groups.
    2 context sentences
    Summary · context
    A total of 51 people with type 2 diabetes of 2.6 ± 1.9 years' duration were randomized to daily subcutaneous liraglutide or placebo injection and followed for 48 weeks, with an oral glucose tolerance test (OGTT) every 12 weeks.
    Summary · context
    GLP-1 and GIP responses were assessed according to their respective area under the curve (AUC) from measurements taken at 0, 30, 60, 90 and 120 minutes during each OGTT.
  2. 02HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes, chronic liraglutide did not change fasting GLP-1 versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change the body's own fasting GLP-1 compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting GLP-1
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    although fasting GLP-1 was unaffected
    2 context sentences
    Summary · context
    A total of 51 people with type 2 diabetes of 2.6 ± 1.9 years' duration were randomized to daily subcutaneous liraglutide or placebo injection and followed for 48 weeks, with an oral glucose tolerance test (OGTT) every 12 weeks.
    Summary · context
    GLP-1 and GIP responses were assessed according to their respective area under the curve (AUC) from measurements taken at 0, 30, 60, 90 and 120 minutes during each OGTT.
  3. 03HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes, chronic liraglutide about doubled the endogenous GLP-1 response to an oral glucose challenge at 12, 24, 36 and 48 weeks versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide roughly doubled the body's own GLP-1 response to a glucose drink compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseEndogenous GLP-1 response (AUC) during OGTT
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    AUC GLP-1 ratio
    ≈ 2 fold
    liraglutide vs placebo

    Source sentences

    Summary
    By contrast, although fasting GLP-1 was unaffected, the liraglutide arm had ~2-fold higher AUCGLP-1 at 12 weeks ( P  < .001), 24 weeks ( P  < .001), 36 weeks ( P  = .03) and 48 weeks ( P  = .03), as compared with placebo.
    2 context sentences
    Summary · context
    A total of 51 people with type 2 diabetes of 2.6 ± 1.9 years' duration were randomized to daily subcutaneous liraglutide or placebo injection and followed for 48 weeks, with an oral glucose tolerance test (OGTT) every 12 weeks.
    Summary · context
    GLP-1 and GIP responses were assessed according to their respective area under the curve (AUC) from measurements taken at 0, 30, 60, 90 and 120 minutes during each OGTT.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.